Avita Medical, Inc. (RCEL)

NASDAQHealth CareMedical - DevicesSnapshot 2026-10-23

$15.51+0.58%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Avita Medical, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	24M
EPS	—	-0.189
FY 2026 · Annual
Revenue	$86M–$89M	87.5M
EPS	—	-0.946
FY 2027 · Annual
Revenue	—	110.16M
EPS	—	-0.385

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Manage debt and capital allocation to support growth	A supporting condition in Avita Medical, Inc.'s published investment case. The stated target is No new debt issues that worsen leverage.	Intact	New debt issuance that increases financial risk materially	No new debt issuance reported No new debt issuance events detected in recent news or filings. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Management delivers on growth initiatives and leadership stability	A supporting condition in Avita Medical, Inc.'s published investment case. The stated target is Maintain or improve progress score above 70%.	Intact	Progress score falls below 50% or leadership changes disrupt growth	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $19.3 million in 2026-Q1 to $21.7 million in 2026-Q2, an 18% year-over-year increase and 13% sequential growth. Management emphasizes growth driven by RECELL and portfolio expansion, and the trajectory is delivering. Delivery assessment Oct 24, 2026
Losses reduce and move toward breakeven	A primary condition in Avita Medical, Inc.'s published investment case. The stated target is EPS loss narrows toward -$0.35 next quarter and improves thereafter.	Improving	EPS loss worsens beyond -$0.5 next quarter	Diluted EPS: $-0.25 per share FY2026-Q4; GAAP. Published target: EPS loss narrows toward -$0.35 next quarter and improves thereafter. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.25 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 300cef8a-5bdc-40f5-8d64-7585781e04c5. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue grows to about $82.5M in 2026	A primary condition in Avita Medical, Inc.'s published investment case. The stated target is ~$82.5M.	Intact	Revenue falls below $70M in FY26	Revenue: $21.702M FY2026-Q4; GAAP. Published target: ~$82.5M. Target period is not explicitly aligned with this observation. Source published Aug 6, 202621,702,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q4 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 300cef8a-5bdc-40f5-8d64-7585781e04c5. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Revenue grew from $19.3 million in 2026-Q1 to $21.7 million in 2026-Q2, an 18% year-over-year increase and 13% sequential growth. Management emphasizes growth driven by RECELL and portfolio expansion, and the trajectory is delivering. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.15B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$151,834,570	4 / 7
2026-07-25	Unavailable	$151,834,570	4 / 7
2026-07-26	Unavailable	$151,834,570	4 / 7
2026-07-27	Unavailable	$151,834,570	4 / 7
2026-07-28	Unavailable	$100,050,000	3 / 5
2026-07-29	Unavailable	$151,834,570	4 / 7
2026-07-30	Unavailable	$100,050,000	3 / 5
2026-07-31	Unavailable	$100,050,000	3 / 5
2026-08-01	Unavailable	$100,050,000	3 / 5
2026-08-02	Unavailable	$151,834,570	4 / 7
2026-08-03	Unavailable	$151,834,570	4 / 7
2026-08-04	Unavailable	$100,050,000	3 / 5
2026-08-05	Unavailable	$100,050,000	3 / 5
2026-08-06	Unavailable	$100,050,000	3 / 5
2026-08-07	Unavailable	$100,050,000	3 / 5
2026-08-08	Unavailable	$152,605,000	3 / 7
2026-08-09	Unavailable	$152,605,000	3 / 7
2026-08-10	Unavailable	$100,050,000	3 / 5
2026-08-12	Unavailable	$156,971,430	3 / 7
2026-08-13	Unavailable	$100,050,000	3 / 5
2026-08-14	Unavailable	$100,050,000	3 / 5
2026-08-15	Unavailable	$100,050,000	3 / 5
2026-08-16	Unavailable	$100,050,000	3 / 5
2026-08-17	Unavailable	$100,050,000	3 / 5
2026-08-18	Unavailable	$100,050,000	3 / 5
2026-08-19	Unavailable	$100,050,000	3 / 5
2026-08-20	Unavailable	$110,100,000	3 / 5
2026-08-21	Unavailable	$110,100,000	3 / 5
2026-08-22	Unavailable	$110,100,000	3 / 5
2026-08-23	Unavailable	$110,100,000	3 / 5
2026-08-24	Unavailable	$110,100,000	3 / 5
2026-08-25	Unavailable	$110,100,000	3 / 5
2026-08-26	Unavailable	$110,100,000	3 / 5
2026-08-27	Unavailable	$110,100,000	3 / 5
2026-08-28	Unavailable	$110,100,000	3 / 5
2026-08-29	Unavailable	$110,100,000	3 / 5
2026-08-30	Unavailable	$110,100,000	3 / 5
2026-08-31	Unavailable	$110,100,000	3 / 5
2026-09-01	Unavailable	$110,100,000	3 / 5
2026-09-02	Unavailable	$110,100,000	3 / 5
2026-09-03	Unavailable	$110,100,000	3 / 5
2026-09-04	Unavailable	$110,100,000	3 / 5
2026-09-05	Unavailable	$110,100,000	3 / 5
2026-09-06	Unavailable	$110,100,000	3 / 5
2026-09-07	Unavailable	$110,100,000	3 / 5
2026-09-08	Unavailable	$110,100,000	3 / 5
2026-09-09	Unavailable	$110,100,000	3 / 5
2026-09-10	Unavailable	$110,100,000	3 / 5
2026-09-11	Unavailable	$110,100,000	3 / 5
2026-09-12	Unavailable	$110,100,000	3 / 5
2026-09-13	Unavailable	$110,100,000	3 / 5
2026-09-14	Unavailable	$110,100,000	3 / 5
2026-09-15	Unavailable	$110,157,143	3 / 5
2026-09-16	Unavailable	$110,157,143	3 / 5
2026-09-17	Unavailable	$110,157,143	3 / 5
2026-09-18	Unavailable	$110,157,143	3 / 5
2026-09-19	Unavailable	$110,157,143	3 / 5
2026-09-20	Unavailable	$110,157,143	3 / 5
2026-09-21	Unavailable	$110,157,143	3 / 5
2026-09-22	Unavailable	$110,157,143	3 / 5
2026-09-23	Unavailable	$110,157,143	3 / 5
2026-09-24	Unavailable	$110,157,143	3 / 5
2026-09-25	Unavailable	$110,157,143	3 / 5
2026-09-26	Unavailable	$110,157,143	3 / 5
2026-09-27	Unavailable	$110,157,143	3 / 5
2026-09-28	Unavailable	$110,157,143	3 / 5
2026-09-29	Unavailable	$110,157,143	3 / 5
2026-09-30	Unavailable	$110,157,143	3 / 5
2026-10-01	Unavailable	$110,157,143	3 / 5
2026-10-02	Unavailable	$110,157,143	3 / 5
2026-10-03	Unavailable	$110,157,143	3 / 5
2026-10-04	Unavailable	$110,157,143	3 / 5
2026-10-05	Unavailable	$110,157,143	3 / 5
2026-10-06	Unavailable	$110,157,143	3 / 5
2026-10-07	Unavailable	$110,157,143	3 / 5
2026-10-08	Unavailable	$110,157,143	3 / 5
2026-10-09	Unavailable	$110,157,143	3 / 5
2026-10-10	Unavailable	$110,157,143	3 / 5
2026-10-11	Unavailable	$110,157,143	3 / 5
2026-10-12	Unavailable	$110,157,143	2 / 5
2026-10-13	Unavailable	$110,157,143	1 / 5
2026-10-14	Unavailable	Unavailable	3 / 3
2026-10-15	Unavailable	Unavailable	3 / 3
2026-10-16	Unavailable	Unavailable	3 / 3
2026-10-17	Unavailable	Unavailable	3 / 3
2026-10-18	Unavailable	Unavailable	3 / 3
2026-10-19	Unavailable	Unavailable	3 / 3
2026-10-20	Unavailable	Unavailable	3 / 3
2026-10-21	Unavailable	Unavailable	3 / 3
2026-10-22	Unavailable	Unavailable	3 / 3
2026-10-23	Unavailable	Unavailable	3 / 3
2026-10-24	Unavailable	Unavailable	3 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	3	2
2026-06-01	3	1
2026-07-01	2	1
2026-08-01	3	1
2026-09-01	3	0
2026-10-01	3	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 3 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Management delivers on growth initiatives and leadership stabilityDirect metric needs a verified mapping
Losses reduce and move toward breakevenDiluted EPS: $-0.25 per share
Revenue grows to about $82.5M in 2026Revenue: $21.702M

Next proof point

Nov 5, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-32.6%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Avita Medical, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

RCEL is a higher-risk growth business, not yet a proven profitable compounder. The multi-year view is on watch: revenue growth is progressing, while recent financial performance remains below its industry cohort.

What's priced into Avita Medical, Inc.

The valuation model shows RCEL at a substantial premium to peers, with low confidence in that comparison. Its priced-in status is tagged justified and no fragility gates fired, but the negative expectations gap suggests the market’s assumptions may leave limited room for execution to disappoint.

What the fundamentals likely do

Near term, revenue growth is the clearest positive: second-quarter revenue rose 18% year over year and 13% sequentially, while gross margin remained near 82%. Operating expenses were lower year over year, but expense discipline is rated behind, and RCEL remains loss-making with elevated risk and erratic recent earnings surprises.

What Avita Medical, Inc. hinges on

Over the next few quarters, the thesis depends on maintaining growth without reversing the recently raised guidance, while improving expense discipline and protecting margins. A weakening jobs trend could weigh on cyclical healthcare names, while continued strong results and guidance from sector peers could support the sector backdrop.